Differences between soluble complement-fixing antigens derived from P3HR-1, RAJI, and Hk-Ly-28 cell lines
Journal of the National Cancer Institute
|March 1, 1975
Summary
Soluble antigens from Epstein-Barr virus (EBV)-associated tumors exhibit distinct stability profiles. Differences in chemical and physical stability differentiate EBV antigens from Burkitt lymphoma and nasopharyngeal cancer cell lines.
Area of Science:
- Virology
- Immunology
- Oncology
Background:
- Epstein-Barr virus (EBV) is associated with various cancers, including Burkitt lymphoma and nasopharyngeal cancer.
- Soluble complement-fixing (CF) antigens are crucial for identifying EBV-associated tumors.
- Understanding the properties of these antigens is vital for diagnostic test development.
Purpose of the Study:
- To characterize and differentiate soluble CF antigens from different EBV-associated cancer cell lines.
- To investigate the stability of these antigens under various chemical and physical conditions.
- To inform the development of diagnostic and purification methods for EBV-related antigens.
Main Methods:
- Extraction of soluble CF antigens from P3HR-1, RAJI (Burkitt lymphoma), and Hk-Ly-28 (nasopharyngeal cancer) cell lines.
- Identification of antigens using viral capsid antigen-positive human sera.
- Assessment of antigen stability through heating and exposure to acid perchlorate.
Main Results:
- Soluble CF antigens from the studied cell lines showed distinct stability profiles.
- The P3HR-1 soluble CF antigen was less stable, losing titer upon heating or acid perchlorate exposure.
- RAJI and Hk-Ly-28 soluble antigens demonstrated greater stability under the same conditions, with solubility differences also noted.
Conclusions:
- Distinct chemical and physical stability properties differentiate soluble EBV-associated antigens.
- These findings aid in interpreting the relationship between EBV components in different cancer cell lines.
- The results provide a basis for selecting optimal conditions for developing identification tests and purification procedures for EBV-related antigens.


